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The history of thiopurines (azathioprine, 6-mercaptopurine) and Crohn’s disease has been many 
years in the making. In 1979 Summers reported on behalf of the National Cooperative Crohn’s 
Disease Study (NCCDS) that azathioprine (AZA) 2.5 mg/kg/day was not effective for induction 
of remission over 16 weeks, or for maintenance of remission therapy over 1 year-.1 In 1980 
Present reported that 6-mercaptopurine (6MP) 1.5 mg/kg/day was effective as induction and 
maintenance therapy over 1 year.2 In this trial, the mean time to response was reported to be 3.1 
months, requiring up to 6 months to reach maximal clinical efficacy in some patients. Due to 
these contradictory data, for the next decade, there was controversy regarding the efficacy of 
thiopurine medications for Crohn’s disease. In 1995, Pearson and Sutherland performed a meta-
analysis which concluded that thiopurines were effective for induction and maintenance therapy , 
and that clinical results were optimized if patients were treated for at least 16 weeks.3 Thereafter, 
thiopurine use in Crohn’s disease gained widespread acceptance, and has been incorporated into 
multiple treatment guidelines.4, 5  
However, the treatment effect of thiopurines for Crohn’s disease has continued to be 
inconsistent. The most recent Cochrane Library meta-analyses reported that thiopurines are not 
effective for induction of remission6, but are effective for maintenance of remission and for 
steroid sparing7, and another meta-analysis reported efficacy of thiopurines for prevention of 
post-operative recurrence.8  
Given the inconsistency of treatment effects, controversy has persisted regarding the appropriate 
role of thiopurines in the treatment of Crohn’s disease. Clinical trials published over the last 10 
plus years have demonstrated that the maximum clinical effect of thiopurines plateaus after 8 
weeks of therapy9, 10 and that the absolute rates of remission are in the range of 25-30%1, 9, 10. 
When risks and benefits of therapy are discussed, it must to be kept in mind  that thiopurines are 
associated with important toxicities including non-Hodgkins lymphoma linked to the Epstein 
Barr virus11-13, hepatosplenic T cell lymphoma14, and non-melanoma skin cancer.15 Comparative 
effectiveness trials demonstrated that thiopurine monotherapy was less effective than 
combination therapy with thiopurines and TNF antagonists for induction and maintenance of 
steroid free remission over 6-12 months.10, 16  
 
In 2000, Markowitz and colleagues reported that 6MP significantly lessened the need for 
prednisone and improved maintenance of remission in a study of 55 pediatric patients with new 
onset Crohn’s disease who received a tapering course of prednisone.17 However, the precise 
details of the reported results are that by 3 months, all 6MP patients and all but 1 placebo patient 
had achieved at  least 1 inactive  Harvey Bradshaw score, and that by 12  months, both groups 
had cumulative remission rates of 89%. Among those in remission, 1 patient (4%) in the 6MP 
group had a relapse within 180 days of achieving remission, compared with 7 patients (28%) in 
the placebo group (p value not given). Based on this study, it has subsequently been proposed 
that “top down” therapy with thiopurines and a tapering course of steroids could serve as an 
alternative to the more recently described treatment strategy of top down therapy with TNF 
antagonists in patients with newly diagnosed or early Crohn’s disease.18 However, given that the 
Markowitz trial only had 55 patients, was conducted in pediatric patients, and did not 
demonstrate definitive differences in remission rates, more data were needed to better assess the 
efficacy of combination therapy with a thiopurine and steroids in adult patients with newly 
diagnosed Crohn’s disease. In this issue of Gastroenterology contains the results of two such 
studies, reported by Cosnes and Panes.19, 20 
Cosnes (for the GETAID group) reported on an open-label randomized trial in 147 adult patients 
with newly diagnosed CD (less than 6 months) and risk factors for disabling disease (patients 
were considered at high risk of disabling disease based on the presence of at least two of the 
following criteria: age < 40 years, active perianal lesions, and corticosteroid use within 3 months 
of diagnosis) recruited at 24 French centers.19 The patients were randomized to receive early 
immunosuppression with AZA 2.5 mg/kg/day or conventional management. Prednisone or 
budesonide was administered for disease flares, and if necessary patients could be switched to 
other immunosuppressive medications and could receive anti-TNF therapy. Among the 
conventional management patients, 61% eventually received AZA.  Among early AZA patients, 
25% had to be switched to another immunosuppressant due to intolerance to AZA. The primary 
end-point, which was the proportion of trimesters spent in steroid-free and anti-TNF-free 
remission during an observation period of 3 years, occurred in 67% of the early AZA group and 
56% of the conventional management group (p=0.69). For the secondary endpoints, there were 
no significant differences between the two groups in the proportions of trimesters with disease 
flare, hospitalization, intestinal surgery or use of TNF antagonists, with the exception of the 
proportion of CD patients not requiring perianal surgery which was higher in the early-AZA 
group (p=0.036).  Total exposure to prednisone and budesonide were also not significantly 
different between the groups. Cosnes concluded that early AZA was not more effective than 
conventional management in adult patients with newly diagnosed CD for increasing time on 
clinical remission over 3 years after diagnosis. 
 
Panes (for the AZTEC study group) reported on a double-blind, placebo-controlled trial in 131 
adult patients with newly diagnosed CD (less than 8 weeks) recruited at 31 Spanish centers.20 
Patients were randomized to receive AZA 2.5 mg/kg/day or placebo. Approximately 70% of 
patients were received steroids at baseline, and subsequently prednisone or budesonide was 
administered for disease flares (defined as a CDAI score greater than 175 points). The primary 
end-point, steroid-free remission at 76 weeks, occurred in 44% of the early AZA group and 37% 
of the placebo group (p=0.48). For the secondary endpoints, there were no significant differences 
between the groups in the proportion of patients with steroid free remission at week 28 or week 
50, and there were no significant differences in relapse free survival rates, or in CDAI scores or 
CRP concentrations over time. The use of steroids was not significantly different between the 
groups. In a post-hoc subgroup analysis, when relapse was defined as an increase in the CDAI 
score to greater than 220 points, then the relapse rate was significantly lower in the early AZA 
group (12% versus 30% in the placebo group, p=0.01). Panes concluded that in early AZA was 
not more effective than placebo in adult patients with newly diagnosed CD for achieving 
sustained steroid-free remission over 76 weeks.  
 
Where does this additional information leave the practicing gastroenterologist and the patient? 
First, the primary endpoints for these two studies demonstrate that early “top down” therapy with 
thiopurine therapy is not more effective that placebo or conventional therapy in adults with 
newly diagnosed CD (although some subgroups of patients may have benefited).19, 20 These 
results cast some doubt as to whether the results of a small pediatric study have any relevance for 
adult patients with newly diagnosed CD.17  Second, we should acknowledge that the most recent 
Cochrane Library meta-analysis demonstrated that thiopurines are not effective for induction of 
remission in CD.6 Third, the most recent Cochrane Library meta-analysis demonstrated that 
thiopurines are modestly effective for maintenance of steroid induced remission7, and another 
meta-analysis demonstrated a modest effect for prevention of post-operative recurrence.8 With 
regard to these two indications, it must be kept in mind that when thiopurines are combined with 
corticosteroids, the relative risks of serious infection and mortality from infection are markedly 
increased.21, 22   
 
Thus, the two remaining indications for primary therapy with thiopurines are maintenance of 
steroid induced remission/steroid sparing in patients with CD which is not newly diagnosed7, and 
prevention of post-operative recurrence8, each of which has a modest effect size that must be 
weighed against the risks of the medications. Two comparative effectiveness trials have 
demonstrated unequivocal superiority of combination therapy with thiopurines and TNF 
antagonist therapy with infliximab as compared with thiopurines alone, with no incremental 
increase in toxicity.10, 16 Therefore, the strongest indication for thiopurines may be as part of a 
combination therapy regimen. The recent post-hoc study reporting that combination therapy is 
more effective with infliximab than with adalimumab or certolizumab23 is not reassuring, given 
that patients were not randomized to TNF antagonist monotherapy or combination therapy, and 
the results are not logical since drug withdrawal data with certolizumab show rates of 
immunogenicity with monotherapy that approach those observed with infliximab.24 There are not 
yet comparative effectiveness data for thiopurines and TNF antagonists for the indication of 
prevention of post-operative recurrence, but early data suggest a very large effect size for TNF 
antagonists.25, 26 If TNF antagonists had a similar low cost as generic thiopurines, there would 
likely be little debate regarding an evolution towards treatment of CD with TNF antagonists, 
either as monotherapy or ideally as combination therapy. Unfortunately, this is not the world that 
we live in. Currently, the annual costs of TNF antagonists is 10-20 times that of thiopurines, and 
large differences in costs are likely to persist even after the advent of biosimilars.27 In 
rheumatoid arthritis (RA), the use of TNF antagonists in very early RA provides the highest level 
of efficacy, but the use of methotrexate is the most cost effective strategy, thus providing the best 
value for society.28 Although the efficacy of methotrexate in RA is more robust than the efficacy 
of thiopurines in CD, the analogy nevertheless persists. Because of the big difference in cost 
between thiopurines and TNF antagonists, the use of thiopurines in CD is likely to persist, 
despite the shrinking number of indications, the modest effect size, and the sub-optimal safety 
profile.  
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